Search company, investor...


Founded Year



Debt - III | Dead

Total Raised


Last Raised


About MiCardia

MiCardia is dedicated to designing, developing and commercializing methods for treating heart disease. The company is developing enCor, a dynamically activated annuloplasty device that corrects residual mitral regurgitation, intra-operatively, on a beating heart. A second generation device, using the dynamic technology, will begin clinical trials in Q4 of 2010. The enCorSQ is unique in its ability to effect recurrent mitral regurgitation days, months or years after the initial procedure, without an additional surgery.

Headquarters Location

30 Hughes # 206

Irvine, California, 92618,

United States


Missing: MiCardia's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MiCardia's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

MiCardia Patents

MiCardia has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Cardiac surgery, Valvular heart disease, Cardiac anatomy, Cardiac arrhythmia, Heart diseases


Application Date


Grant Date



Related Topics

Cardiac surgery, Valvular heart disease, Cardiac anatomy, Cardiac arrhythmia, Heart diseases



Latest MiCardia News

MiCardia Corp Medical Equipment Deals and Alliances Profile Report Updated 17072017 Prices from USD $250

Aug 24, 2017

MiCardia Corp Medical Equipment Deals and Alliances Profile [Report Updated: 17072017] Prices from USD $250 00:40 EDT 24 Aug 2017 | BioPortfolio Reports Home » Topics » Medical Devices » Latest News » MiCardia Corp Medical Equipment Deals and Alliances Profile [Report Updated: 17072017] Prices from USD $250 Summary MiCardia Corp MiCardia is a medical device company that designs, develops, and commercializes minimal invasive methods for treatment of heart diseases. The company offers implantable devices in the treatment of heart diseases such as mitral valve regurgitation and congestive heart failure. It also provides annuloplasty rings to restore the annulus of the valve. MiCardia's products are used for heart valve repair and replacement, mitral valve repair, revascularization to treat coronary artery disease. Its enCorS technology is used for recurrent mitral regurgitation to be managed on an outpatient basis. The company operates in the Netherlands, Italy, the US, Spain, Germany, Austria and the UK. MiCardia is headquartered in Irvine, California, the US. MiCardia Corp Medical Equipment Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Medical eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

MiCardia Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MiCardia Rank

MiCardia Frequently Asked Questions (FAQ)

  • When was MiCardia founded?

    MiCardia was founded in 2004.

  • Where is MiCardia's headquarters?

    MiCardia's headquarters is located at 30 Hughes, Irvine.

  • What is MiCardia's latest funding round?

    MiCardia's latest funding round is Debt - III.

  • How much did MiCardia raise?

    MiCardia raised a total of $27.5M.

  • Who are the investors of MiCardia?

    Investors of MiCardia include BioStar Capital, MedFocus Fund, HBM Partners and Japan Asia Investment Group.

  • Who are MiCardia's competitors?

    Competitors of MiCardia include Angel Medical Systems, Ancora Heart, Broncus Medical, Respicardia, Cardiac Dimensions, Mitralign, ReShape Medical, Neotract, CircuLite, BridgePoint Medical and 18 more.

Compare MiCardia to Competitors

Cardiac Power

Cardiac Power is a non-blood-contacting left ventricular assist device for the treatment of congestive heart failure

NeoChord Logo

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.


CardioMetrix is a medical device company developing implantable technologies to assist physicians in managing patients suffering from congestive heart failure (CHF).


CardioKinetix develops a percutaneous treatment for patients with left ventricular dilation after an anterior myocardial infarction (MI). The implantable device, called the PARACHUTE is a partitioning membrane deployed within the compromised ventricle. The PARACHUTE partitions the damaged muscle, isolating the non-functional muscle segment from the functional segment, and decreases the overall volume. Options for patients whose ventricle has enlarged are limited, with most on medical therapy and/or a cardiac resynchronization device that only benefits heart failure patients with a specific EKG pattern.


CoRepair, Inc. is developing a radiofrequency (RF) device system for the treatment of congestive heart failure.


Viacor is a development stage company dedicated to pioneering catheter-based techniques for the treatment of congestive heart failure.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.